Following cessation of therapy for acute rheummiatic fever manifestations of rheumatic activity frequently reapp2ar. The incidence of these manifestations and their severity were studied during the 3-week observational period in 257 patients treated as part of the Cooperative Clinical Trial on the treatment of rheumatic fever. From the analysis of these manifestations certain concepts iliay be deprived concerning diagnostic and therapeutic criteria.
W I1EN hormone or salicylate therapy for acute rheumatic feever is discontinued there is frequently a reappearance or persistence of manifestations of rheumatic activity. These Because the current analysis is concerned with the description of the post-therapy period, the data from all 3 treatment groups have been combined. Cardiac The number of manifestations exhibited during the post-therapy period varied with the cardiac status on admission, there being more manifestations with more severe initial involvement. In table 3 the 257 children are grouped according to the cardiac status at the start of therapy. The first 2 groups represent first attacks of rheumatic fever, with or without carditis. Children with prior heart disease are next listed. Finally, 33 children with failure or pericarditis are presented, three fourths of whom were in their first known attack.
There was also a great number of manifestations during the post-therapy period in those patients who were first treated 6 weeks or more after the onset of their illness (table  4) . It is not known whether this increase is due to the selective factor of late therapy itself or to other factors. There is no difference between the groups treated 0 to 14 days from onset and those treated 14 to 42 days.
These data suggest several interpretations concerning the significance of the post-therapy period. The apparent relationship between the duration and severity of the rheumatic process before therapy and the frequency with which abnormalities appear after withdrawal of therapy is again indicative of the relationship of the "rebound" to the basic disease.
If the "rebound" were solely a drug-induced phenomenon, unrelated to rheumatic fever, such a relationship would not be expected.
The importance of the post-therapy exacerbation during its acute phase is dramatically apparent in those few patients, 4 , who first experienced cardiac failure or pericarditis at that time. One of these patients died, despite prompt reinstitution of therapy. Six patients had a recurrence or continuation of failure and pericarditis during the period following therapy.5 In some instances the severity of the disease during the post-therapy period was as great or greater than at the start of treatment. In most instances, the various abnormalities subsided spontaneously. Retreatment was considered necessary for only 6 patients. It is difficult to assess the contribution of the rebound to the development of permanent valvular or myocardial damage. Under the conditions of therapy, prophylaxis, and 1 year follow-up of the Cooperative Clinical Trial, it appears that in most instances no effect could be attributed to the recurrence of inflammatory reaction after discontinuation of therapy. Nevertheless, the extent of heart damage may be related to the severity and duration of rheumatic inflammatory reaction, whether this occurs before, during, or after suppressive therapy. Just as it appears judicious to avoid recurrent attacks of rheumatic fever by prophylaxis, so it may be of value to avoid exacerbations of rheumatic in-MANIFESTATIONS OF RHEUMATIC FEVER From the nature of the rebound we may also deduce some of the areas in which the drugs had an effect, however incomplete. When any or all of the presenting manifestations of rheumatic activity subside during drug therapy, the effect may be attributed to several possible causes: spontaneous remission in the course of the disease, bed rest, or to the drug administered. Following cessation of therapy, the recurrence of rheumatic manifestations is ample evidence that the drug employed did not eradicate the disease. However, it is also evidence, in retrospect, that the drug had a suppressive action while it was being administered. It was widely taught that aspirin did not affect the rheumatic inflammation in the heart (and that concept has occasionally been extended to cortisone). The recurrence of heart failure or pericarditis after cessation of either drug conflicts with that view. A flare-up of the disease process would not be expected if a totally ineffective agent were discontinued.
SUMMARY
The 3-week period following cessation of therapy was studied in 257 children with Le studio del periodo post-therapeutic provide possibilemente un certe perspectiva concernente le criterios diagnostic e le efficacia del agentes therapeutic (judicate in retrospecto). Le manifestationes del periodo post-tractamental es satis commun sub apparentemente bon conditiones de providentia. Le studio de iste periodo debe esser includite in tentativas de definir optimos therapeutic pro febre rheumatic.
